**Name of Journal:** *World Journal of Transplantation*

**Manuscript NO:** 74772

**Manuscript Type:** ORIGINAL ARTICLE

***Retrospective Study***

**Reduced upper limb lean mass on dual energy X-ray absorptiometry predicts adverse outcomes in male liver transplant recipients**

Hey P *et al*. DEXA in post-liver transplant outcomes

Penelope Hey, Rudolf Hoermann, Paul Gow, Timothy P Hanrahan, Adam G Testro, Ross Apostolov, Marie Sinclair

**Penelope Hey, Paul Gow, Timothy P Hanrahan, Adam G Testro, Ross Apostolov, Marie Sinclair,** Liver Transplant Unit, Austin Health, Heidelberg 3084, Australia

**Penelope Hey, Rudolf Hoermann, Paul Gow, Adam G Testro, Ross Apostolov, Marie Sinclair,** Department of Medicine, University of Melbourne, Melbourne 3052, Australia

**Author contributions:** All authors have contributed to this manuscript and have agreed on the content; Hey P and Sinclair M were involved in the study design; Hey P and Hanrahan TP performed data collection; Hoermann R performed statistical analysis; Hey P, Gow P, Testro AG, Apostolov R and Sinclair M, were involved in data interpretation, drafting and revising the work; and all authors provided approval of the final version to be published.

**Corresponding author: Penelope Hey, FRACP, MBBS, Research Fellow, Staff Physician,** Liver Transplant Unit, Austin Health, 145 Studley Road, Heidelberg 3084, Australia. penny.hey@austin.org.au

**Received:** January 10, 2022

**Revised:** April 24, 2022

**Accepted: May 22, 2022**

**Published online:**

**Abstract**

BACKGROUND

Pre-transplant muscle wasting measured by computed tomography has been associated with adverse clinical outcomes after liver transplantation including increased rates of sepsis and hospitalisation days. Upper limb lean mass (LM) measured by dual-energy X-ray absorptiometry (DEXA) was recently identified as a novel predictor of sarcopenia-associated mortality in men waitlisted for transplantation.

AIM

To investigate the use of DEXA LM in predicting gender-stratified early post-transplant outcomes.

METHODS

Liver transplant recipients who underwent pre-transplant DEXA body composition imaging between 2002 and 2017 were included. Endpoints included post-transplant mortality and graft failure, bacterial infections, acute cellular rejection (ACR) and intensive care and total hospital length of stay.

RESULTS

Four hundred and sixty-nine patients met inclusion criteria of which 338 were male (72%). Median age was 55.0 years (interquartile range 47.4, 59.7) and model for end-stage liver disease (MELD) score 16. Median time from assessment to transplantation was 7 mo (3.5, 12). Upper limb LM was inversely associated with bacterial infections at 180 d post-transplant (hazard ratio = 0.42; 95% confidence interval: 0.20-0.89; *P* = 0.024) in males only. There was a negative correlation between upper limb LM and intensive care (τb = -0.090, *P* = 0.015) and total hospital length of stay (τb = -0.10, *P* = 0.0078) in men. In women, neither MELD nor body composition parameters were associated with post-transplant adverse outcomes or increased length of stay. Body composition parameters, MELD and age were not associated with 90-d mortality or graft failure in either gender. There were no significant predictors of early ACR.

CONCLUSION

Sarcopenia is an independent and potentially modifiable predictor of increased post-transplant bacterial infections and hospital length of stay in men with cirrhosis. DEXA upper limb LM provides a novel measure of muscle wasting that has prognostic value in this cohort. The lack of association in women requires further investigation.

**Key Words:** Dual-energy X-ray absorptiometry; Sarcopenia; Body composition; Liver transplantation; Survival

Hey P, Hoermann R, Gow P, Hanrahan TP, Testro AG, Apostolov R, Sinclair M. Reduced upper limb lean mass on dual energy X-ray absorptiometry predicts adverse outcomes in male liver transplant recipients. *World J Transplant* 2022; In press

**Core Tip:** Pre-transplant sarcopenia as measured by single-slice computed tomography has prognostic value in predicting outcomes in liver transplant recipients. In this retrospective study, we explore the association of pre-transplant dual-energy X-ray absorptiometry (DEXA) body composition analysis with early post-transplant outcomes. Low upper limb lean mass (LM) was a predictor of 180-d post-transplant bacterial infections and longer hospital and intensive care length of stay in men but not women. Upper limb LM was superior to other measures of LM including appendicular LM in predicting adverse outcomes. There was no association between pre-transplant body composition and post-transplant mortality, graft failure or early acute cellular rejection. In conclusion, pre-transplant sarcopenia is associated with adverse outcomes in men after liver transplantation. Upper limb LM provides a novel measure of muscle mass that is superior to other measures of LM on DEXA in predicting early post-transplant outcomes.

**INTRODUCTION**

Sarcopenia is a syndrome defined by decreased muscle mass and reduced strength or function[1]. It is estimated to affect between 40% and 70% of patients waitlisted for liver transplantation depending on the modality used to measure muscle mass[2]. Sarcopenia is a predictor of waitlist mortality, independent of model for end-stage liver disease (MELD) score[3]. Muscle wasting measured using the cross-sectional muscle area at the third lumbar vertebrae on computed tomography (CT) is associated with longer hospital length of stay and increased risk of post-operative complications following liver transplantation[4,5].

There is emerging evidence for the role of dual-energy X-ray absorptiometry (DEXA) body composition to quantify muscle mass in cirrhosis. DEXA provides whole body compartmentalised measurements of bone mineral content, fat mass and lean tissue. It has the advantage of being a simple, reproducible, low-cost technique that can be performed easily on outpatients being worked up for transplantation. Results are readily available without the need for further analysis or dedicated software. The major limitation for the use of DEXA in cirrhosis is that it can be influenced by hydration status including the presence of ascites and oedema. To reduce the impact of ascites, appendicular lean mass (APLM), the sum of LM in arms and legs corrected for height is the preferred measure for sarcopenia in cirrhosis.

We recently identified that upper limb LM was a novel, independent predictor of sarcopenia-associated mortality in men waitlisted for transplantation[6]. Upper limb LM rather than total APLM has the advantage of being unaffected by peripheral oedema. This study aims to describe the associations between pre-transplant gender-specific body composition measurements and early post-transplant outcomes.

**MATERIALS AND METHODS**

***Study design***

This study retrospectively analysed data of all adult patients (> 18 years) who underwent liver transplantation at a tertiary centre in Melbourne, Australia, between January 2002 and July 2018. Exclusion criteria included transplantation for non-cirrhotic indications, redo liver transplantation, multi-visceral transplants and those missing DEXA body composition data at transplant assessment. Approval was obtained by the Austin Health Human Ethics Research Committee.

***Clinical and laboratory assessments***

Baseline demographics including age and aetiology of liver disease were recorded at transplant assessment. Clinical examination findings including presence of hepatic encephalopathy and ascites were recorded by a transplant hepatologist. Ascites was graded as requiring no treatment, diuretic therapy alone or paracentesis. Body mass index was calculated at the time of the DEXA. Biochemistry and haematology were measured at transplant assessment, all within 6 wk of the DEXA scan. Laboratory assessments included bilirubin, serum creatinine, international normalized ratio and serum albumin to enable calculation of MELD and Child Pugh Scores. Operative data at the time of liver transplantation was collected including cold and warm ischaemic time (minutes), operative time (minutes), and blood transfusion requirement (units).

***Body composition assessment***

DEXA body composition analysis was performed at the time of transplant assessment using a Lunar Prodigy DEXA scanner (GE Healthcare, Madison, WI. United States). This quantified compartmentalised total body composition including LM, fat mass and bone mass. Variables analysed included appendicular, upper limb, lower limb and total LM and fat mass. All measurements were corrected for height2. Sarcopenia was defined by previously reported cut-off values for APLM from the European Working Group on Sarcopenia in older people (males < 7.26 kg/m2, females < 5.5 kg/m2)[7,8].

***Clinical endpoints***

Clinical endpoints were examined at 90 d, 180 d and 12 mo post transplantation and included mortality, graft failure, bacterial infections, and acute cellular rejection (ACR). Graft failure was defined as graft loss requiring re-transplantation or due to patient death. Bacterial infections required the identification of a causative pathogen treated with systemic antimicrobial therapy. ACR was biopsy proven, defined as a rejection activity index ≥ 4 based on Banff criteria. Other outcomes included post-transplant intensive care stay (hours), hospital length of stay (days) and discharge destination (discharge to home or subacute care). Length of stay data excluded patients who died within the early post-operative period, within 48 h of transplantation.

***Peri-operative and early post-operative management***

Orthotopic liver transplantation was performed according to unit protocol and included both donation after brain death and donation after cardiac death. Organ allocation was based on the MELD scoring system. Protocolised immunosuppression comprised intravenous corticosteroids administered from day 0 to day 5 post-transplantation followed by a weaning course of oral corticosteroids. A combination of oral calcineurin inhibitors (cyclosporin or tacrolimus) and either mycophenolate mofetil or azathioprine were initiated early post-transplantation. A gradual switch from azathioprine to mycophenolate mofetil was made following Therapeutic Goods Administration approval of the latter medication in Australia in 2012. Intravenous basiliximab was administered at day 0 and 5 in patients with impaired renal function to allow delayed commencement of calcineurin inhibitors.

***Statistical analysis***

Continuous variables were expressed as a median and interquartile range (25th and 75th percentile). Chi squared and fisher’s exact tests were used for categorical variables. Continuous variables were compared using students *t* test (normal distribution) or Mann-Whitney *U* test (without normal distribution). Kendall Rank correlations were used to assess correlations between pre-transplant variables and post-transplant intensive care and hospital length of stay.

Survival analysis was used to follow patients after liver transplantation until they had died, experienced a complication such as bacterial infection or graft failure, or their status had last been audited. Univariate Cox proportional hazard regression analysis was used to identify predictors of 90-d and 12-mo post-transplant mortality and graft failure. Univariate and multivariate Cox regression analyses were used to identify predictors of 90 and 180-d post-transplant bacterial infections and 90-d ACR. Two-sided *P* < 0.05 conferred significance for all tests. The statistical software package R 4.1.2 for Mac with the survival package 3.2-13 was used for the analyses[9,10].

**RESULTS**

***Baseline patient characteristics***

Between January 2002 and December 2018, 859 adults underwent liver transplantation (Figure 1). Four-hundred and sixty-nine patients had available pre-transplant DEXA body composition data and met the inclusion criteria. Three-hundred and thirty-eight (72%) were male. The median age was 55.0 years (interquartile range 47.4, 59.7) and MELD score 16 (Table 1). The most common indications for liver transplantation were decompensated cirrhosis caused by viral hepatitis (*n* = 138, 29%) and alcohol (*n* = 51, 11%). Hepatocellular carcinoma in the context of cirrhosis was the primary indication for transplantation in 122 patients (26%). At transplant assessment, 259 (55%) patients had ascites, of which 137 (29%) had required recent paracentesis. A history of hepatic encephalopathy was reported in 220 patients (47%). The median time from assessment to transplantation was 7 mo (3.5, 12).

***Body composition assessment***

Using DEXA body composition assessment, the median APLM was 7.91 kg/m2 (7.15, 8.71) for males and 6.50 kg/m2 (5.87, 7.36) for females. Based on previously reported cut-off values[7], 95 men (28%) and 19 women (15%) were sarcopenic (Table 1). Women had higher fat mass, 7.56 kg/m2 (5.48, 9.95) compared to men, 6.41 kg/m2 (4.70, 9.31), *P* = 0.018.

***Mortality and graft failure***

At 90 d and 12 mo post transplantation, 15 (3.2%) and 33 (7.0%) of patients respectively had died. 12-mo post-transplant survival increased in the latter half of the period examined from 90% in 2002-2009 to 96% in 2010-2018. Pre-transplant body composition parameters, MELD and age were not associated with 90-d or 12-mo post-transplant mortality in men. Higher total LM but no other LM parameters was associated with 12-mo mortality in women [hazard ratio (HR) = 1.22; 95% confidence interval (CI): 1.04-1.44; *P* = 0.017]. Peri-operative blood transfusion requirements was associated with 90-d and 12-mo mortality in both men (HR = 1.21; 95%CI: 1.06-1.39; *P* = 0.006) and women (HR = 1.24; 95%CI: 1.10-1.40, *P* = 0.006). Of the 15 patients who died within 90 d of transplantation, only 3 met previously reported DEXA-based gender-specific diagnostic criteria for sarcopenia using APLM[7].

At 90 d and 12 mo post transplantation, 22 (4.6%) and 43 (9.2%) of patients respectively had graft failure. Body composition parameters, MELD and presence of ascites at workup were not associated with 90-d or 12-mo graft failure in men. Higher intra-operative blood transfusion requirement was associated with 90-d graft failure in both genders. Longer operative time was also associated with 90-d graft failure in men only (HR = 1.004; 95%CI: 0.001-1.008; *P* = 0.017).

***Post-transplant bacterial infection***

At 90 d and 180 d post-transplant, 59 (17.5%) and 73 (21.6%) men respectively had suffered a bacterial infection. Reduced upper limb LM was associated with bacterial infections in men at 180 d only, HR = 0.42; 95%CI: 0.20-0.89 (Table 2). The presence of ascites at transplant assessment was associated with 90-d and 180-d post-transplant bacterial infection in men only. Body composition parameters, MELD score, ascites and operative variables did not show an association with 90-d or 180-d bacterial infections in women.

***ACR***

At 90 d post transplantation, 105 patients (22.4%) had an episode of moderate to severe ACR. In men, 90-d ACR was negatively associated the presence of ascites (HR = 0.93; 95%CI: 0.89-0.97, *P* = 0.0021) and MELD sore (Table 3). Similarly, lower total lean mass (TLM) was associated with higher 90-d ACR (HR = 0.83; 95%CI: 0.75-0.92; *P* < 0.001) whereas APLM and upper limb mass were not. 90-d ACR was not associated with body composition parameters, MELD or the presence of ascites in women. Peri-operative blood transfusion requirement was negatively associated with 90-d ACR in men but not women (HR = 0.89; 95%CI: 0.81-0.99; *P* = 0.026). Other operative data was not associated with ACR in either gender.

***Length of stay***

The median intensive care stay following liver transplantation was 66 and hospital length of stay was 15 d in men but not women, upper limb LM was inversely associated with longer intensive care stay (τb = -0.090, *P* = 0.015) and hospital length of stay (τb = -0.10, *P* = 0.0078) (Figure 2 and Table 4). The presence of ascites at transplant assessment was associated with longer intensive care and hospital stay in men (median 15 d *vs* 4 d, *P* = 0.024) but not women (Figure 3). In men only, a higher peak alanine transaminase also correlated with longer intensive care stay (τb = 0.13, *P* < 0.001), but not total hospital length of stay. There was no significant difference in intensive care or hospital length of stay in patients who were classified as sarcopenic based on gender-specific cut offs for APLM.

***Interaction between MELD, ascites and DEXA body composition parameters***

Pre-transplant MELD and the presence of ascites at work up showed differing relationships with DEXA body composition parameters.

**MELD and body composition:** Upper limb LM negatively correlated with increasing MELD score in men but not women (men: τb = -0.14, *P* < 0.001, women; τb = -0.077, *P* = 0.20). Increasing TLM and lower limb LM correlated with higher MELD score in both genders (Table 5).

**Ascites and body composition:** Compared to those without, ascites was associated with lower upper limb LM in men [median 1.83 kg/m2 (1.63, 2.03) *vs* 2.02 kg/m2 (1.86, 2.20), *P* < 0.001). Conversely, TLM was higher in those with ascites [median 20.0 kg/m2 (18.4, 22.1) *vs* 18.7 kg/m2 (17.2, 20.2), *P* < 0.001]. In women, the presence of ascites was associated with TLM only [median 16.9 kg/m2 (15.7, 19) *vs* 16.2 kg/m2 (14.4, 17.3), *P* = 0.004].

**Ascites and MELD:** With rising MELD, the prevalence of ascites increased (risk ratio for ascites 4.79 ± 0.58, *P* < 0.001).

**DISCUSSION**

This study investigates the impact of pre-transplant DEXA body composition on outcomes after liver transplantation. We identified reduced upper limb LM as a novel predictor of adverse outcomes including bacterial infections and longer hospital stay in men only. We did not find any significant association between body composition and post-transplant graft-failure or mortality, which suggests that prioritizing patients with sarcopenia for transplantation may be an appropriate strategy to minimize waitlist mortality without a negative impact on post-transplant survival[6].

Previous studies investigating the impact of pre-transplant sarcopenia on post-transplant survival have shown conflicting outcomes[5,11,12]. This disparity may relate to differing definitions of sarcopenia, modalities used for muscle mass assessment, severity of liver disease and inadequate power of some studies to adequately assess mortality. In this study, we describe excellent patient and graft survival of 93% and 91% respectively at 12 mo post-transplant. Era of transplantation may also be a factor as advancements in peri-operative care and immunosuppressive agents have improved post-transplant survival in the modern era. The higher 12-mo post-transplant survival observed in the latter half of the period likely reflects improvements in medical care, despite the increasing medical complexity and older age of transplant recipients. Further large-scale multi-centre studies using reproducible measures of sarcopenia that incorporate muscle function and potential deterioration on the waitlist are required to better elucidate the impact of pre-transplant sarcopenia on post-transplant survival. This will help to determine whether prioritising sarcopenic patients is appropriate and whether a threshold exists below which these patients are indeed too sick for transplantation.

Pre-transplant sarcopenia, as defined by CT imaging, has been consistently reported to be associated with increased post-transplant sepsis. In keeping with this, our study found that upper limb LM was associated with bacterial infections in men at 180-d post-transplant. No significant association was found at 90-d post-transplant, likely reflecting our relatively low infection rate of 21% at this time point as compared to other studies[13]. Our definition of bacterial infections, requiring the identification of a causative pathogen, may result in a lower incidence of early post-transplant bacterial infection leading to inadequate power to detect an association with pre-transplant muscle parameters. The influence of pre-transplant sarcopenia and frailty on early post-transplant ACR is also uncertain with conflicting reports in the literature[14,15]. This study found no association between pre-transplant sarcopenia and early ACR. This provides reassurance that optimising sarcopenia pre-transplant does not appear to result in higher rates of ACR.

While muscle area measured on transverse abdominal CT is often considered gold standard for quantifying muscle mass in cirrhosis, practice guidelines recommend against the use of CT for the sole purposes of sarcopenia assessment due to high radiation doses[16]. In addition to CT, DEXA and bioelectrical impedance are recommended by the European Working Group for Sarcopenia in Older People for assessment of muscle mass[1]. DEXA has advantages over CT due to its reproducibility, low cost and radiation and no requirement for further analysis. However, the inability of DEXA to differentiate fluid and lean tissue is particularly problematic in decompensated cirrhosis where the occurrence of ascites and peripheral oedema are high.

Current guidelines recommend the use of APLM for defining sarcopenia using DEXA with cut-off values extrapolated from non-cirrhotic cohorts for both men and women[1,7]. In a small prospective series of men with cirrhosis, APLM did not change following large volume paracentesis suggesting this is not confounded by ascites[17]. However, the influence of peripheral oedema in this population has not been well described. Similar to our prior work[6], this study demonstrates the superiority of upper limb LM in predicting post-transplant outcomes in patients with cirrhosis when compared to APLM, lower limb LM and TLM. As MELD rose, upper limb LM decreased whereas lower limb LM and TLM increased. This suggests that in decompensated cirrhosis, upper limb LM more accurately reflects true muscle mass as it is not confounded by peripheral oedema or ascites. A cut-off of upper limb LM of < 1.6 kg/m2 was the best predictor of waitlist mortality in a single-centre cohort of men with cirrhosis[6]. This cut-off requires validation in multicentre cohorts and as yet no definitions for sarcopenia using upper limb LM have been proposed for women.

A major finding in this study is the lack of association of pre-transplant muscle parameters with post-transplant outcomes in women. This remains an unanswered question in the literature. While a sex-stratified approach to diagnose sarcopenia is required, most studies fail to report on gender-specific mortality analyses. Like most studies in the field of cirrhosis, women accounted for less than a third of patients transplanted for cirrhosis in this cohort. This may lead to inadequate power to detect significant associations between sarcopenia and outcomes.

It is possible that muscle mass has greater prognostic significance in men than women. The pathogenesis of sarcopenia in cirrhosis is a complex interplay between multiple factors. Testosterone, a potent promoter of muscle growth, plays a particularly important role in the development of sarcopenia in men. Testosterone levels fall with progression of liver disease and correlate with muscle mass in men with cirrhosis[18,19]. Furthermore, there is a clear association between testosterone levels in cirrhotic men and the adverse outcomes of hepatic decompensation, need for liver transplantation and death[20]. This may explain the higher prevalence of low muscle mass in men waitlisted for transplantation compared to women[21].

Functional measures of muscle such as handgrip strength and the liver frailty index may carry better prognostic utility in women. A multi-centre study of patients waitlisted for liver transplantation in the United States found that women had higher frailty scores than men and that increased frailty was associated with higher waitlist mortality[22]. A major limitation of this study is that muscle strength was not included due to the lack of available data over the timeframe described. Larger studies describing sarcopenia-related outcomes in cirrhotic and liver transplant cohorts need to include functional measures of sarcopenia and provide gender-stratified analyses so we can better understand the role of muscle in predicting outcomes in each gender.

**CONCLUSION**

In conclusion, this study is the first to comprehensively describe the association of reduced muscle mass as measured by DEXA on post-liver transplant outcomes providing gender-stratified analyses. We identify upper limb LM as a novel measure of sarcopenia that is associated with adverse outcomes post-liver transplant in men, without a corresponding increase in mortality. Larger multi-centre studies that provide gender-stratified monitoring of muscle mass and function serially on the waitlist are required to assess the full impact of sarcopenia on post-transplant outcomes. This will help determine whether prioritizing patients with sarcopenia for transplantation may be an appropriate strategy to minimize waitlist mortality without compromising post-transplant survival.

**ARTICLE HIGHLIGHTS**

***Research background***

Pre-transplant sarcopenia defined by reduced skeletal muscle index measured by transverse abdominal computed tomography (CT) is associated with adverse outcomes after liver transplantation. These include increased rates of sepsis, longer hospital length of stay and a possible increase in post-transplant mortality.

***Research motivation***

CT is not recommended for use solely for the purpose of diagnosing sarcopenia given the high radiation doses. Dual-energy X-ray absorptiometry (DEXA) body composition assessment provides a low radiation and reproducible alternative for measuring muscle mass with prognostic utility in the pre-transplant setting. Upper limb lean mass (LM) has recently been identified as a novel assessment of sarcopenia using DEXA.

***Research objectives***

This study investigates the use of DEXA body composition assessment in predicting gender-stratified early post-transplant outcomes.

***Research methods***

This study retrospectively analysed liver transplant recipients who underwent pre-transplant DEXA body composition imaging between 2002 and 2017 at a single-centre. DEXA variables analysed included appendicular LM (APLM), total, upper and lower limb LM and fat mass corrected for height2. Endpoints included post-transplant mortality and graft failure, bacterial infections, acute cellular rejection and intensive care and total hospital length of stay (days).

***Research results***

Four hundred and sixty-nine patients met inclusion criteria of which 338 were male (72%). Upper limb LM was inversely associated with bacterial infections at 180 d post-transplant in males only. There was a negative correlation between upper limb LM and intensive care and total hospital length of stay in men. In women, neither model for end-stage liver disease (MELD) nor body composition parameters were associated with post-transplant adverse outcomes or increased length of stay. Body composition parameters, MELD and age were not associated with 90-d mortality or graft failure in either gender.

***Research conclusions***

Upper limb LM measured on DEXA is a novel measure of sarcopenia with better prognostic value compared to APLM in predicting adverse outcomes after liver transplantation. Reduced upper limb LM was a predictor of post-transplant bacterial infection and longer length of stay in men only, but was not associated with increased mortality or graft failure. The lack of association in women requires further investigation.

***Research perspectives***

Larger multi-centre studies that provide gender-stratified analysis of muscle mass and function serially on the waitlist are required to assess the full impact of pre-transplant sarcopenia on post-transplant outcomes. This will help determine whether prioritizing patients with sarcopenia for transplantation may be an appropriate strategy to minimize waitlist mortality without compromising post-transplant survival.

**REFERENCES**

1 **Cruz-Jentoft AJ**, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, Cooper C, Landi F, Rolland Y, Sayer AA, Schneider SM, Sieber CC, Topinkova E, Vandewoude M, Visser M, Zamboni M; Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2. Sarcopenia: revised European consensus on definition and diagnosis. *Age Ageing* 2019; **48**: 16-31 [PMID: 30312372 DOI: 10.1093/ageing/afy169]

2 **Kim G**, Kang SH, Kim MY, Baik SK. Prognostic value of sarcopenia in patients with liver cirrhosis: A systematic review and meta-analysis. *PLoS One* 2017; **12**: e0186990 [PMID: 29065187 DOI: 10.1371/journal.pone.0186990]

3 **Lai JC**, Feng S, Terrault NA, Lizaola B, Hayssen H, Covinsky K. Frailty predicts waitlist mortality in liver transplant candidates. *Am J Transplant* 2014; **14**: 1870-1879 [PMID: 24935609 DOI: 10.1111/ajt.12762]

4 **Hamaguchi Y**, Kaido T, Okumura S, Kobayashi A, Shirai H, Yagi S, Kamo N, Okajima H, Uemoto S. Impact of Skeletal Muscle Mass Index, Intramuscular Adipose Tissue Content, and Visceral to Subcutaneous Adipose Tissue Area Ratio on Early Mortality of Living Donor Liver Transplantation. *Transplantation* 2017; **101**: 565-574 [PMID: 27926595 DOI: 10.1097/TP.0000000000001587]

5 **Montano-Loza AJ**, Meza-Junco J, Baracos VE, Prado CM, Ma M, Meeberg G, Beaumont C, Tandon P, Esfandiari N, Sawyer MB, Kneteman N. Severe muscle depletion predicts postoperative length of stay but is not associated with survival after liver transplantation. *Liver Transpl* 2014; **20**: 640-648 [PMID: 24678005 DOI: 10.1002/lt.23863]

6 **Sinclair M**, Hoermann R, Peterson A, Testro A, Angus PW, Hey P, Chapman B, Gow PJ. Use of Dual X-ray Absorptiometry in men with advanced cirrhosis to predict sarcopenia-associated mortality risk. *Liver Int* 2019; **39**: 1089-1097 [PMID: 30746903 DOI: 10.1111/liv.14071]

7 **Baumgartner RN**, Koehler KM, Gallagher D, Romero L, Heymsfield SB, Ross RR, Garry PJ, Lindeman RD. Epidemiology of sarcopenia among the elderly in New Mexico. *Am J Epidemiol* 1998; **147**: 755-763 [PMID: 9554417 DOI: 10.1093/oxfordjournals.aje.a009520]

8 **Cruz-Jentoft AJ**, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, Martin FC, Michel JP, Rolland Y, Schneider SM, Topinková E, Vandewoude M, Zamboni M; European Working Group on Sarcopenia in Older People. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. *Age Ageing* 2010; **39**: 412-423 [PMID: 20392703 DOI: 10.1093/ageing/afq034]

9 **R Core Team**. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna. 2021. [cited 13 December 2021]. Available from: https://www.R-project.org/

10 **Therneau TM,** Grambsch PM. Modelling Survival Data: Extending the Cox Model. New York: Springer, 2000

11 **Hanai T**, Shiraki M, Nishimura K, Ohnishi S, Imai K, Suetsugu A, Takai K, Shimizu M, Moriwaki H. Sarcopenia impairs prognosis of patients with liver cirrhosis. *Nutrition* 2015; **31**: 193-199 [PMID: 25441595 DOI: 10.1016/j.nut.2014.07.005]

12 **van Vugt JL**, Levolger S, de Bruin RW, van Rosmalen J, Metselaar HJ, IJzermans JN. Systematic Review and Meta-Analysis of the Impact of Computed Tomography-Assessed Skeletal Muscle Mass on Outcome in Patients Awaiting or Undergoing Liver Transplantation. *Am J Transplant* 2016; **16**: 2277-2292 [PMID: 26813115 DOI: 10.1111/ajt.13732]

13 **Kalafateli M**, Mantzoukis K, Choi Yau Y, Mohammad AO, Arora S, Rodrigues S, de Vos M, Papadimitriou K, Thorburn D, O'Beirne J, Patch D, Pinzani M, Morgan MY, Agarwal B, Yu D, Burroughs AK, Tsochatzis EA. Malnutrition and sarcopenia predict post-liver transplantation outcomes independently of the Model for End-stage Liver Disease score. *J Cachexia Sarcopenia Muscle* 2017; **8**: 113-121 [PMID: 27239424 DOI: 10.1002/jcsm.12095]

14 **Wakabayashi T**, Shinoda M, Obara H, Kitago M, Yagi H, Abe Y, Matsubara K, Yamada Y, Oshima G, Hirukawa K, Mizota T, Hibi T, Itano O, Hoshino K, Kuroda T, Kitagawa Y. Decreased Incidence of Acute Cellular Rejection in Low-Muscle-Mass Recipients After Living-donor Liver Transplantation. *Transplant Proc* 2018; **50**: 3626-3634 [PMID: 30577248 DOI: 10.1016/j.transproceed.2018.06.028]

15 **Fozouni L**, Mohamad Y, Lebsack A, Freise C, Stock P, Lai JC. Frailty Is Associated With Increased Rates of Acute Cellular Rejection Within 3 Months After Liver Transplantation. *Liver Transpl* 2020; **26**: 390-396 [PMID: 31655014 DOI: 10.1002/lt.25669]

16 **Lai JC**, Tandon P, Bernal W, Tapper EB, Ekong U, Dasarathy S, Carey EJ. Malnutrition, Frailty, and Sarcopenia in Patients With Cirrhosis: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. *Hepatology* 2021; **74**: 1611-1644 [PMID: 34233031 DOI: 10.1002/hep.32049]

17 **Belarmino G**, Gonzalez MC, Sala P, Torrinhas RS, Andraus W, D'Albuquerque LAC, Pereira RMR, Caparbo VF, Ferrioli E, Pfrimer K, Damiani L, Heymsfield SB, Waitzberg DL. Diagnosing Sarcopenia in Male Patients With Cirrhosis by Dual-Energy X-Ray Absorptiometry Estimates of Appendicular Skeletal Muscle Mass. *JPEN J Parenter Enteral Nutr* 2018; **42**: 24-36 [PMID: 28402708 DOI: 10.1177/0148607117701400]

18 **Grossmann M**, Hoermann R, Gani L, Chan I, Cheung A, Gow PJ, Li A, Zajac JD, Angus P. Low testosterone levels as an independent predictor of mortality in men with chronic liver disease. *Clin Endocrinol (Oxf)* 2012; **77**: 323-328 [PMID: 22280063 DOI: 10.1111/j.1365-2265.2012.04347.x]

19 **Sinclair M**, Grossmann M, Angus PW, Hoermann R, Hey P, Scodellaro T, Gow PJ. Low testosterone as a better predictor of mortality than sarcopenia in men with advanced liver disease. *J Gastroenterol Hepatol* 2016; **31**: 661-667 [PMID: 26414812 DOI: 10.1111/jgh.13182]

20 **Deng N**, Mallepally N, Peng FB, Kanji A, Marcelli M, Hernaez R. Serum testosterone levels and testosterone supplementation in cirrhosis: A systematic review. *Liver Int* 2021; **41**: 2358-2370 [PMID: 33966337 DOI: 10.1111/liv.14938]

21 **Tandon P**, Ney M, Irwin I, Ma MM, Gramlich L, Bain VG, Esfandiari N, Baracos V, Montano-Loza AJ, Myers RP. Severe muscle depletion in patients on the liver transplant wait list: its prevalence and independent prognostic value. *Liver Transpl* 2012; **18**: 1209-1216 [PMID: 22740290 DOI: 10.1002/lt.23495]

22 **Lai JC**, Ganger DR, Volk ML, Dodge JL, Dunn MA, Duarte-Rojo A, Kappus MR, Rahimi RS, Ladner DP, Boyarsky B, McAdams-DeMarco M, Segev DL, McCulloch CE, Verna EC. Association of Frailty and Sex With Wait List Mortality in Liver Transplant Candidates in the Multicenter Functional Assessment in Liver Transplantation (FrAILT) Study. *JAMA Surg* 2021; **156**: 256-262 [PMID: 33377947 DOI: 10.1001/jamasurg.2020.5674]

**Footnotes**

**Institutional review board statement:** This study was approved through the Austin Health Human Research Ethics Committee.

**Informed consent statement:** The informed consent statement was waived.

**Conflict-of-interest statement:** All authors declare no conflict-of-interest related to this article.

**Data sharing statement:** No additional data are available.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed

**Peer-review model:** Single blind

**Peer-review started:** January 10, 2022

**First decision:** April 13, 2022

**Article in press:**

**Specialty type:** Transplantation

**Country/Territory of origin:** Australia

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C, C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Li HL, China; Schemmer P, Austria **A-Editor:** Yao QG, China **S-Editor:** Wang JJ **L-Editor:** A **P-Editor:**

**Figure Legends**

 

**Figure 1 Flowchart of inclusion and exclusion of patients undergoing liver transplantation.** DEXA: Dual-energy X-ray absorptiometry.



**Figure 2 Correlation of upper limb lean mass and hospital length of stay in men.** Correlations are given in the text.



**Figure 3 The presence of ascites at transplant assessment and the impact on hospital length of stay in men.** *P* values are given in the text.

**Table 1** **Baseline patient characteristics based on gender and presence of sarcopenia defined by low appendicular lean mass[8]**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Non-sarcopenic (*n* = 355, 75.7%)** | **Sarcopenic (*n* = 114, 24.3%)** | ***P* value** |
| Age, indication for transplantation | 55 (48, 60) | 54 (46, 58) | 0.253 |
| Viral hepatitis  | 106 (30%) | 32 (28%) | 0.715 |
| Alcohol | 30 (8%) | 21 (18%) | 0.003a |
| Hepatoma | 96 (27%) | 26 (23%) | 0.370 |
| PBC/PSC/AIH | 66 (19%) | 18 (16%) | 0.497 |
| Bilirubin (μmol/L) | 57 (28, 114) | 47.5 (25, 91.5) | 0.324 |
| Albumin (g/L) | 29 (24, 33) | 30 (25, 25) | 0.172 |
| INR | 1.4 (1.2, 1.7) | 1.4 (1.2, 1.6) | 0.786 |
| Ascites | 188 (53%) | 71 (62%) | 0.082 |
| Encephalopathy | 163 (46%) | 57 (50%) | 0.401 |
| MELD score | 16 (12, 20) | 16 (12, 19) | 0.934 |
| Operative data |  |  |  |
| Total operative time (min) | 465 (397, 534) | 445 (291, 510) | 0.162 |
| Peak ALT | 884 (509, 1525) | 933 (496, 1494) | 0.991 |
| Cold ischaemic time (min) | 381 (318, 479) | 384 (303, 473) | 0.530 |
| Warm ischaemic time (min) | 45 (39, 52) | 44 (38, 50) | 0.212 |
| RBC transfusions (units) | 2 (0, 4) | 2 (0, 5) | 0.008a |

a*P* value < 0.05.

PBC: Primary biliary cholangitis; PSC: Primary sclerosing cholangitis; AIH: Autoimmune hepatitis; INR: International normalized ratio; MELD: Model for end stage liver disease; ALT: Alanine transaminase; RBC: Red blood cell.

**Table 2** **The association of pre-transplant variables and 180-d post-transplant sepsis**

|  |  |  |
| --- | --- | --- |
|  | **Males (*n* = 338)** | **Females (*n* = 131)** |
| **HR (95%CI)** | ***P* value** | **HR (95%CI)** | ***P* value** |
| MELD | 1.04 (1.00, 1.08) | 0.051 | 1.06 (0.99, 1.12) | 0.074 |
| APLM | 1.03 (0.87, 1.21) | 0.76 | 0.93 (0.70, 1.24) | 0.63 |
| Upper limb LM | 0.42 (0.20, 0.89) | 0.024a | 0.74 (0.19, 2.95) | 0.67 |
| Lower limb LM | 1.09 (0.92, 1.30) | 0.33 | 0.93 (0.67, 1.28) | 0.66 |
| Total LM | 1.07 (0.99, 1.15) | 0.08 | 0.89 (0.76, 1.03) | 0.12 |
| Total fat mass | 0.98 (0.91, 1.05) | 0.50 | 0.99 (0.90, 1.08) | 0.76 |
| Ascites | 2.18 (1.32, 3.59) | 0.002a | 2.14 (0.95, 4.82) | 0.06 |

a*P* value < 0.05.

MELD: Model for end stage liver disease; APLM: Appendicular lean mass; LM: Lean mass; HR: Hazard ratio; CI: Confidence interval.

**Table 3** **The association of pre-transplant variables and acute cellular rejection within ninety days of liver transplantation**

|  |  |  |
| --- | --- | --- |
|  | **Males (*n* = 338)** | **Females (*n* = 131)** |
| **HR (95%CI)** | ***P* value** | **HR (95%CI)** | ***P* value** |
| MELD | 0.93 (0.89, 0.97) | 0.002 | 1.04 (0.99, 1.09) | 0.14 |
| APLM | 0.87 (0.72, 1.05) | 0.16 | 1.10 (0.87. 1.4) | 0.43 |
| Upper limb LM | 1.34 (0.67, 2.68) | 0.41 | 0.43 (0.12, 1.51) | 0.19 |
| Lower limb LM | 0.80 (0.63, 1.01) | 0.063 | 1.17 (0.90, 1.52) | 0.23 |
| Total LM | 0.83 (0.74, 0.92) | < 0.001a | 1.05 (0.95, 1.17) | 0.32 |
| Total fat mass | 0.93 (0.87, 1.00) | 0.062 | 1.03 (0.95, 1.12) | 0.50 |
| BMI | 0.91 (0.86, 0.96) | < 0.001a | 1.02 (0.97, 1.08) | 0.45 |
| Ascites | 0.43 (0.26, 0.70) | < 0.001a | 1.51 (0.76, 3.00) | 0.24 |

a*P* value < 0.05.

MELD: Model for end stage liver disease; APLM: Appendicular lean mass; LM: Lean mass; BMI: Body mass index; HR: Hazard ratio; CI: Confidence interval.

**Table 4 Correlation of variables at transplant assessment with post-transplant total hospital and intensive care length of stay**

|  |  |  |
| --- | --- | --- |
|  | **Males (*n* = 338)** | **Females (*n* = 131)** |
| **Correlation1 (τb)** | ***P* value1** | **Correlation2 (τb)** | ***P* value2** | **Correlation1 (τb)** | ***P* value1** | **Correlation2 (τb)** | ***P* value2** |
| Age | < -0.001 | 0.98 | 0.055 | 0.14 | 0.084 | -0.18 | 0.047 | 0.44 |
| Total APLM | -0.027 | 0.48 | -0.004 | 0.91 | -0.029 | 0.65 | -0.012 | 0.84 |
| Upper limb LM | -0.10 | 0.0078a | -0.090 | 0.015a | -0.079 | 0.21 | 0.019 | 0.75 |
| Lower limb LM | < 0.001 | 0.99 | 0.017 | 0.64 | -0.018 | 0.76 | -0.018 | 0.76 |
| Total LM | 0.32 | 0.037a | 0.055 | 0.13 | -0.012 | 0.84 | -0.012 | 0.84 |
| Total fat mass | 0.036 | 0.33 | 0.048 | 0.20 | 0.039 | 0.53 | 0.039 | 0.53 |
| MELD | 0.078 | 0.045a | 0.0087 | 0.058 | -0.037 | 0.56 | 0.087 | 0.17 |

a*P* value < 0.05.

1Correlation of variables at transplant assessment with post-transplant total hospital length of stay.

2Correlation of variables at transplant assessment with post-transplant intensive care length of stay.

APLM: Appendicular lean mass; LM: Lean mass; MELD: Model for end stage liver disease.

**Table 5 Correlation of model for end stage liver disease score and body composition parameters**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Males (τb)** | ***P* value** | **Females (τb)** | ***P* value** |
| APLM | 0.071 | 0.056 | 0.15 | 0.01a |
| Upper limb LM | -0.14 | < 0.001a | -0.077 | 0.20 |
| Lower limb LM | 0.12 | < 0.001a | 0.18 | 0.0024a |
| Total LM | 0.22 | < 0.001a | 0.18 | 0.0036a |
| Fat mass | -0.04 | 0.27 | -0.097 | 0.11 |

a*P* value < 0.05.

APLM: Appendicular lean mass; LM: Lean mass.